Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of SP2086 With Hepatic Insufficiency
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06035406
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- HER2-expressing Advanced Solid Tumors
- Interventions
- Drug: SHR-A1811 combined with Pyrotinib.Drug: SHR-A1811 combined with other antitumor therapies
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT06015048
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Lymphoma
- Interventions
- Drug: [14C]SHR2554
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06010680
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
Phase 1
Not yet recruiting
- Conditions
- Advanced Prostate Cancer
- Interventions
- Drug: HRS-4357 injection
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT06006104
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT05996380
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects
Phase 3
Active, not recruiting
- Conditions
- Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
- Interventions
- Drug: SHR7280 simulant； Ganirelix Acetate InjectionDrug: SHR7280；Ganirelix Acetate Injection simulant
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 317
- Registration Number
- NCT05994378
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Cancer
- Interventions
- Drug: HRS-7053 Injection
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT05983146
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05954169
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Drug: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumabDrug: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 606
- Registration Number
- NCT05945901
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdog, China
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05942001
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath